Know Cancer

or
forgot password

Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Advanced Solid Tumor

Thank you

Trial Information

Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy


Inclusion Criteria:



- Age ≥ 18 years old.

- Patients with recurrent/persistent metastatic solid tumors on a therapeutic protocol

- There is Sufficient archival tissue for molecular profiling, fresh tumor tissue as
routine standard of care, a plan to obtain or pre-existing molecular profiling
results available.

Exclusion Criteria:

- Unwilling or unable to provide informed consent.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

frequency of "actionable" oncogenic mutations

Outcome Description:

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

David Hyman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

12-245

NCT ID:

NCT01775072

Start Date:

January 2013

Completion Date:

January 2015

Related Keywords:

  • Advanced Solid Tumor
  • tissue
  • blood
  • Genomic Profiling
  • Solid Tumors
  • Clinical Assay
  • Research Assay
  • 12-245

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021